Study	Reason for exclusion
Abraham 1987	Allocation: randomised. Participants: people with schizophrenia. Interventions: trifluoperazine and ECT versus trifluoperazine with simulated ECT.
Barsa 1959	Allocation: not randomised.
Brannen 1969	Allocation: randomised. Participants: people with chronic schizophrenia. Interventions: promethazine versus trifluoperazine versus placebo. Outcomes: no usable data, 57% lost to follow up.
Buffaloe 1961	Allocation: unclear, double‐blind crossover study. Participants: people with schizophrenia. Interventions: first phase only trifluoperazine, second phase trifluoperazine plus parnate versus trifluoperazine. Outcomes: no data available.
Cabrera 1990	Allocation: unclear, double‐blind study. Participants: people with schizophrenia. Interventions: interferon "intratecal" + oral placebo versus trifluoperazine + chlorpromazine + trihexifenidil + lumbar injection of distilled water.
Calwell 1964	Allocation: "randomly divided" ‐ no further description, multiple crossover (medication was changed every 4 weeks). Participants: women with chronic schizophrenia. Interventions: oxypertine versus trifluoperazine. Outcomes: no data reported for first arm of crossover.
Carscallen 1968	Allocation: "double‐blind technique" ‐ no further details. Participants: people with schizophrenia. Interventions: trifluoperazine 10 mg/day versus trifluoperazine 100 mg/day. Outcomes: no data available.
Casey 1961	Allocation: randomised. Participants: people with schizophrenia. Interventions: d‐amphetamine versus isocarboxazid versus imipramine versus trifluoperazine versus placebo but chlorpromazine given to everyone.
Childers 1961	Allocation: not randomised.
Childers 1962	Allocation: randomised. Participants: people with extrapyramidal symptoms. Interventions: benzotropine methanesulfonate plus chlorpromazine or trifluoperazine or fluphenazine versus procyclidine plus chlorpromazine or trifluoperazine or fluphenazine, no data for trifluroperazine group alone.
Childres 1962 b	Allocation: not randomised, "placed in temporal sequence".
Crane 1970	Allocation: randomised. Participants: people with schizophrenia. Interventions: trifluoperazine 80 mg/day versus trifluoperazine 16 mg/day versus placebo. Outcomes: no usable data.
D'Elia 1974	Allocation: randomised. Participants: people with schizophrenia. Interventions: trifluoperazine versus pimozide. Outcomes: EEG study, no data available.
Den Boer 2000	Allocation: double‐blind procedure. Participants: people with schizophrenia. Interventions: neuroleptic treatment (trifluoperazine, chlorpromazine, haloperidol, thioridazine) plus ritanserin versus neuroleptic treatment plus placebo.
Dewolfe 1971	Allocation: randomised, crossover trial. Interventions: prolixin enanthate versus thorazine‐stelazine, not stelazine.
DiMascio 1965	Allocation: randomised Participants: healthy volunteers.
Eitan 1992	Allocation: "were assigned", no further details, double‐blind crossover study . Participants: people with schizophrenia. Interventions: chlorpromazine versus thioridazine versus trifluoperazine versus haloperidol versus placebo. Outcomes: no data reported for individual arms of cross‐over.
Fish 1966	Allocation: not randomised.
Forrester 1958	Allocation: not randomised.
Gardos 1968	Allocation: "were assigned" ‐ no further details. Participants: psychotic patients ‐ no further details. Interventions: two different samples, withdrawn group (trifluoperazine 10 mg versus trifluoperazine 5 mg + chlorpromazine 50 mg) and agitated group (chlorpromazine 200 mg versus trifluoperazine 5 mg+ chlorpromazine 200 mg). Outcomes: no data available.
Gottfries 1971	Allocation: not randomised.
Guido 1960	Allocation: not randomised.
Held 1970	Allocation: randomised. Participants: people with schizophrenia. Interventions: thorazine versus melleril versus stelazine versus prolixin versus proketazine versus trifalon versus haloperidol versus placebo. Outcomes: no usable data.
Janecek 1963	Allocation: not randomised.
Jones 1970	Allocation: not randomised.
Jones 1971	Allocation: not randomised.
Joshi 1980	Allocation: unclear ‐ double‐blind study. Participants: people with schizophrenia. Interventions: combined modality therapy (trifluoperazine + vitamins versus trifluoperazine + placebo).
Joshi 1982	Allocation: unclear ‐ double‐blind. Participants: people with schizophrenia. Interventions: combined modality therapy (trifluoperazine, vitamins B1, B6, B12, chlorpromazine and placebo).
Kalinin 1986	Allocation: randomised. Participants: people with schizophrenia. Interventions: insulin coma therapy versus individual pharmacotherapy (haloperidol, trifluoperazine plus sedatives ‐ amitriptyline and lithium).
Kline 1977	Allocation: not randomised.
Knight 1979	Allocation: double‐blind crossover trial. Participants: people with chronic schizophrenia. Interventions: thiothixene versus combination of trifluoperazine and chlorpromazine.
Lal 1974	Allocation: randomised ‐ crossover study. Participants: people with oral dyskinesia.
Lapolla 1965	Allocation: randomised. Participants: "preponderance of schizophrenia". Interventions: only trifluoperazine, no control group.
Lovett 1987	Allocation: not randomised.
Luckey 1967	Allocation: randomised. Participants: people with schizophrenia. Interventions: haloperidol versus trifluoperazine. Outcomes: 66% of people were not reported in the final analysis.
Macdonald 1959	Allocation: not randomised.
Mandel 1962	Allocation: randomised, crossover trial. Participants: people with schizophrenia. Interventions: trifluoperazine versus butyrylperazine. Outcomes: no usable data.
Mena 1964	Allocation: double‐blind controlled study. Participants: "chronic outpatients".
Monroe 1965	Allocation: randomisation not mentioned, described as controlled. Participants: mixed diagnosis.
Montero 1971	Allocation: "double‐blind". Participants: people with paranoid schizophrenia. Interventions: thioridazine versus trifluoperazine plus chlorpromazine.
Morton 1968	Allocation: randomised ‐ withdrawal study.
Moyano 1975	Allocation: unclear, double‐blind. Participants: people with schizophrenia. Interventions: trifluoperazine versus loxapine succinate.
Oybir 1962	Allocation: not randomised.
Pecknold 1977	Allocation: randomised Participants: people with schizophrenia. Interventions: clomacran versus trifluoperazine. Outcomes: 50% left the study.
Polvan 1971	Allocation: not randomised.
Rudy 1958	Allocation: not randomised.
Schiele 1963	Allocation: randomised. Participants: people with schizophrenia. Interventions: trifluoperazine plus tranilcipromine versus trifluoperazine plus placebo. Outcomes: no data reported for the individual drugs.
Sharpley 1964	Allocation: "double‐blind study". Interventions: pargyline plus tranylcypromine versus pargyline plus tranylcypromine plus trifluoperazine.
Stanley 1961	Allocation: not randomised, case control study.
Talbot 1964	Allocation: unclear. Participants: people with schizophrenia. Interventions: trifluoperazine plus chlorpromazine versus placebo.
Teja 1975	Allocation: randomised. Participants: people with schizophrenia. Interventions: trifluoperazine versus chlorpromazine versus thiothixene versus haloperidol versus placebo. Outcomes: no usable data.
Tetreault 1968	Allocation: randomised. Participants: people with chronic mental disease. Interventions: trial 1 ‐ trifluperidol versus trifluoperazine, trial 2 ‐ TPS‐23 versus chlorpromazine versus placebo. Outcomes: no data available.
Tolan 1959	Allocation: not randomised.
Uddyback 1962	Allocation: not randomised, case series.
Vogt 1961	Allocation: not randomised
Weckowicz 1960	Allocation: not randomised.
Weston 1961	Allocation: randomised. Participants: people with schizophrenia. Interventions: trifluoperazine versus placebo. Outcomes: no data available.
Wilson 1961	Allocation: unclear, "Latin square", crossover design. Participants: people with schizophrenia. Interventions: chlorpromazine versus prochlorperazine versus trifluoperazine versus placebo. Outcomes: no data available.
Winnik 1962	Allocation: not randomised.